ISSN: 1300-7777 E-ISSN: 1308-5263
Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients [Turk J Hematol]
Turk J Hematol. 2018; 35(1): 27-34 | DOI: 10.4274/tjh.2017.0021  

Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients

Özlem Tüfekçi1, Ülker Koçak2, Zühre Kaya2, İdil Yenicesu2, Canan Albayrak3, Davut Albayrak3, Şebnem Yılmaz Bengoa1, Türkan Patıroğlu4, Musa Karakükçü4, Ekrem Ünal4, Elif Ünal İnce5, Talia İleri5, Mehmet Ertem5, Tiraje Celkan6, Gül Nihal Özdemir6, Nazan Sarper7, Dilek Kaçar8, Neşe Yaralı8, Namık Yaşar Özbek8, Alphan Küpesiz, Et Al
1Dokuz Eylül University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey
2Gazi University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey
3Ondokuz Mayıs University Faculty of Medicine, Department of Pediatric Hematology, Samsun, Turkey
4Erciyes University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Kayseri, Turkey
5Ankara University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Ankara, Turkey
6İstanbul University Cerrahpaşa Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey
7Kocaeli University Faculty of Medicine, Department of Pediatric Hematology, Kocaeli, Turkey
8Ankara Children’s Hematology and Oncology Training and Research Hospital, Ankara, Turkey
9Akdeniz University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Antalya, Turkey
10Dr. Behçet Uz Children Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, İzmir, Turkey
11Necmettin Erbakan University Meram Faculty of Medicine, Department of Pediatric Hematology, Konya, Turkey
12Uludağ University Faculty of Medicine, Department of Pediatric Hematology, Bursa, Turkey
13Ege University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey
14Şişli Hamidiye Etfal Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, İstanbul, Turkey
15Bahçeşehir University Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey
16Marmara University Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey
17Karadeniz Technical University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Trabzon, Turkey
18Tepecik Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, İzmir, Turkey

Objective: This study aimed to define the status of juvenile myelomonocytic leukemia (JMML) patients in Turkey in terms of time of diagnosis, clinical characteristics, mutational studies, clinical course, and treatment strategies.
Materials and Methods: Data including clinical and laboratory characteristics and treatment strategies of JMML patients were collected retrospectively from pediatric hematology-oncology centers in Turkey.
Results: Sixty-five children with JMML diagnosed between 2002 and 2016 in 18 institutions throughout Turkey were enrolled in the study. The median age at diagnosis was 17 months (min-max: 2-117 months). Splenomegaly was present in 92% of patients at the time of diagnosis. The median white blood cell, monocyte, and platelet counts were 32.9x109/L, 5.4x109/L, and 58.3x109/L, respectively. Monosomy 7 was present in 18% of patients. JMML mutational analysis was performed in 32 of 65 patients (49%) and PTPN11 was the most common mutation. Hematopoietic stem cell transplantation (HSCT) could only be performed in 28 patients (44%), the majority being after the year 2012. The most frequent reason for not performing HSCT was the inability to find a suitable donor. The median time from diagnosis to HSCT was 9 months (min-max: 2-63 months). The 5-year cumulative survival rate was 33% and median estimated survival time was 30±17.4 months (95% CI: 0-64.1) for all patients. Survival time was significantly better in the HSCT group (log-rank p=0.019). Older age at diagnosis (>2 years), platelet count of less than 40x109/L, and PTPN11 mutation were the factors significantly associated with shorter survival time.
Conclusion: Although there has recently been improvement in terms of definitive diagnosis and HSCT in JMML patients, the overall results are not satisfactory and it is necessary to put more effort into this issue in Turkey.

Keywords: Hematopoietic stem cell transplantation, Juvenile myelomonocytic leukemia, Turkey


Türkiye’de Juvenil Miyelomonositik Lösemi: Altmış Beş Hastanın Retrospektif Analizi

Özlem Tüfekçi1, Ülker Koçak2, Zühre Kaya2, İdil Yenicesu2, Canan Albayrak3, Davut Albayrak3, Şebnem Yılmaz Bengoa1, Türkan Patıroğlu4, Musa Karakükçü4, Ekrem Ünal4, Elif Ünal İnce5, Talia İleri5, Mehmet Ertem5, Tiraje Celkan6, Gül Nihal Özdemir6, Nazan Sarper7, Dilek Kaçar8, Neşe Yaralı8, Namık Yaşar Özbek8, Alphan Küpesiz, Et Al
1Dokuz Eylül University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey
2Gazi University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey
3Ondokuz Mayıs University Faculty of Medicine, Department of Pediatric Hematology, Samsun, Turkey
4Erciyes University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Kayseri, Turkey
5Ankara University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Ankara, Turkey
6İstanbul University Cerrahpaşa Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey
7Kocaeli University Faculty of Medicine, Department of Pediatric Hematology, Kocaeli, Turkey
8Ankara Children’s Hematology and Oncology Training and Research Hospital, Ankara, Turkey
9Akdeniz University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Antalya, Turkey
10Dr. Behçet Uz Children Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, İzmir, Turkey
11Necmettin Erbakan University Meram Faculty of Medicine, Department of Pediatric Hematology, Konya, Turkey
12Uludağ University Faculty of Medicine, Department of Pediatric Hematology, Bursa, Turkey
13Ege University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey
14Şişli Hamidiye Etfal Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, İstanbul, Turkey
15Bahçeşehir University Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey
16Marmara University Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey
17Karadeniz Technical University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Trabzon, Turkey
18Tepecik Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, İzmir, Turkey

Amaç: Türkiye’deki juvenil miyelomonositik lösemi (JMML) hastalarının durumunu, tanı zamanı, klinik özellikler, mutasyon çalışmaları, klinik gidiş ve tedavi stratejileri açısından ortaya koymaktır.
Gereç ve Yöntem: Ülkemizdeki pediatrik hematoloji ve onkoloji kliniklerinden veri istenerek, JMML tanısı ile takip ve tedavisi yapılan hastaların klinik ve laboratuvar bulguları geriye dönük olarak değerlendirildi.
Bulgular: On sekiz merkezden, 2002-2016 tarihleri arasında JMML tanısı alan toplam 65 hasta çalışmaya dahil edildi. Ortanca tanı yaşı 17 ay idi (2-117 ay). Splenomegali tanıda %92 hastada vardı. Ortanca lökosit, monosit ve trombosit sayıları sırasıyla 32,9x109/L, 5,4x109/L ve 58,3x109/L idi. Monozomi 7, %18 hastada saptanmıştı. JMML mutasyonları 32 hastada (%49) çalışılmış olup, en sık rastlanan mutasyon PTPN11 idi. Hematopoetik kök hücre nakli (HKHN) hastaların ancak %44’üne uygulanabilmiş olup, nakillerin büyük bir oranı 2012 yılından sonra yapılmıştı. Nakil yapılamamasının en sık nedeni uygun donör bulunamamasıydı. Tanı aldıktan nakile kadar geçen ortalama süre 9 ay (2-63 ay) olarak saptandı. Tüm hastalarda 5 yıllık kümülatif sağkalım oranı %33, ortanca tahmini yaşam süresi ise 30±17,4 ay (%95 CI: 0-64,1) olarak bulundu. Sağkalım süresi HKHN yapılan hastalarda anlamlı olarak daha uzundu (log-rank p=0,019). Tanıda 2 yaşın üstünde olmak, trombosit sayısının 40x109/L’nin altında saptanması ve PTPN11 mutasyon varlığı yaşam süresini anlamlı olarak kısaltan faktörler olarak bulundu.
Sonuç: Ülkemizde her ne kadar son dönemlerde JMML hastalarında kesin tanı ve HKHN açısından iyileşme kaydedilmiş olsa da genel sonuç tatminkar değildir ve bu konu ile ilgili daha fazla çaba göstermeye gerek vardır.

Anahtar Kelimeler: Hematopoetik kök hücre nakli, Juvenil miyelomonositik lösemi, Türkiye


Özlem Tüfekçi, Ülker Koçak, Zühre Kaya, İdil Yenicesu, Canan Albayrak, Davut Albayrak, Şebnem Yılmaz Bengoa, Türkan Patıroğlu, Musa Karakükçü, Ekrem Ünal, Elif Ünal İnce, Talia İleri, Mehmet Ertem, Tiraje Celkan, Gül Nihal Özdemir, Nazan Sarper, Dilek Kaçar, Neşe Yaralı, Namık Yaşar Özbek, Alphan Küpesiz, Et Al. Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients. Turk J Hematol. 2018; 35(1): 27-34

Corresponding Author: Özlem Tüfekçi, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2017) = 0.650